Eurocastle Investment Limited
2.12.2025 15:15:42 CET | Globenewswire | Press release
Eurocastle announces Director/PDMR Dealing Notification
Eurocastle announces Director/PDMR Dealing Notification
EUROCASTLE INVESTMENT LIMITED
FOR IMMEDIATE RELEASE
Contact:
Oak Fund Services (Guernsey) Limited
Company Administrator
Attn: Nicole Barnes
Tel: +44 1481 752957
Eurocastle Announces Director/PDMR Dealing Notification
Guernsey, 02 December 2025 - By reference to its obligations under Article 19 of EU Regulation 596/2014, Eurocastle Investment Limited is making public the following details of dealings in its shares by persons discharging managerial responsibilities and their closely associated persons:
| Name of PDMR | Financial Instrument | Nature of Transaction | Date and place of Transaction | Volume and price of Transaction |
| Mr. Jason de Beauvoir Sherwill | Ordinary Shares | Purchase of shares | 27 November 2025 | 1,000 shares at EUR 14.80 |
ABOUT EUROCASTLE
Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company. On 8 July 2022, the Company announced the relaunch of its investment activity and is currently in the early stages of pursuing its new strategy by initially focusing on opportunistic real estate in Greece with a plan to expand across Southern Europe. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom